Oral quercetin (250 mg/d for 8 weeks) improved antioxidant response in T2D patients, while significant changes were not observed in glycemic status and lipid profile [95], while a dose is 500 mg/day for a period 8 weeks reduced the plasma glucose levels, suggesting that the dose and duration of quercetin are crucial determinants of its protective function in T2D [96]
In addition, new trials with dose-responsive effect of serum vitamin B12 on NAFLD still need to be explored for this finding
[1] Cell Line:Senescent Leydig cells Concentration:25 mM Incubation Time:3 days Result:Reduced the viability of senescent as compared to normal TM3 Leydig cells
Most trials focus on kids 12+ for obesity management first, then diabetes
Its collaborative research model, which includes partnerships with academic medical centers, pharmaceutical innovators, and community treatment providers, ensures that discoveries are rapidly translated into real-world clinical applications